Large-cap Consumer Discretionary company Series has logged a -0.1% change today on a trading volume of 2,545,339. The average volume for the stock is 27,008,051.
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. Based in Summit, United States the company has 22,000 full time employees and a market cap of $31,098,527,744. Series currently offers its equity investors a dividend that yields 5.1% per year.
The company is now trading -23.92% away from its average analyst target price of $21.3 per share. The 15 analysts following the stock have set target prices ranging from $17.0 to $26.0, and on average give Series a rating of buy.
Over the last 12 months KVUE shares have declined by -24.7%, which represents a difference of -40.6% when compared to the S&P 500. The stock's 52 week high is $25.17 per share and its 52 week low is $15.47. With its net margins declining an average -21.9% over the last 3 years, Series declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 15,455,000 | 1,030,000 | 7 | -36.36 |
| 2023 | 15,444,000 | 1,664,000 | 11 | -21.43 |
| 2022 | 15,054,000 | 2,078,000 | 14 |
